UNSPSC 51182108: Desmopressin acetate

This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2.C2H4O2.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XB13HYU18U, chemically known as vasopressin, 1-(3-mercaptopropanoic acid)-8-d-arginine- but more generally known as desmopressin acetate, which bears US NIH Compound Identifier 27991. European Medicines Agency schedules Desmopressin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01597MIG.

UNSPSC 51182108 Desmopressin acetate is a Commodity code representing pharmaceutical active ingredients and finished-dose products supplied through state and local cooperative purchasing agreements. State and local governments procure desmopressin acetate and related generic pharmaceuticals through multistate cooperative purchasing alliances that consolidate demand across participating state departments, county health systems, municipal clinics, and school district health services. The solicitations typically require suppliers to maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), source products through authorized pharmaceutical wholesalers, and submit detailed product information including National Drug Codes, SKUs, packaging configurations, and manufacturing certifications. Issuing bodies span state health and human services departments, cooperative purchasing organizations, and member jurisdictions across multiple states. The procurement model emphasizes price competitiveness (typically weighted at 75 percent of evaluation), EDI capability, administrative fee structures, and contractual relationships with established wholesaler networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The contract covers participating state and local government facilities across Minnesota, Oregon, and other MMCAP member jurisdictions, with awarded vendors effective July 1, 2026 for a two-year term. Evaluation criteria include fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), agreement to a 3 percent administrative fee (5 percent), and price competitiveness (75 percent). Vendors must maintain commercial general liability coverage of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, with insurance requirements and performance penalties ($200 to $1,500 per violation) enforcing operational standards. No specific set-aside designations are identified in the documentation. Questions close February 18, 2026, and all products must be available in the marketplace by May 15, 2026 with a minimum one-year expiration date and six-month shelf life.